Relapse prevention in alcoholics. A review of acamprosate versus naltrexone

Clinical Drug Investigation

Volumn 17, Issue 3, 1999, Pages 211-216

  Hoes, Melchior J A J M ^a  

^a Ziekenhuis Rivierenland   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACAMPROSATE; DISULFIRAM; NALTREXONE; OPIATE; OPIATE RECEPTOR; THIORIDAZINE;

ABDOMINAL PAIN; ALCOHOLISM; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HEART INFARCTION; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NAUSEA; PHARMACOKINETICS; PRIORITY JOURNAL; PRURITUS; PSYCHOSOCIAL CARE; RASH; RELAPSE; SOMNOLENCE; STOMACH HEMORRHAGE; TREATMENT OUTCOME; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 0033004373     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917030-00005     Document Type: Article

References (28)

1. O'Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med 1998; 338: 592-602
2. Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997; 53: 1038-53
3. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 867-80
4. O'Malley S, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence, a controlled study. Arch Gen Psychiatry 1992; 49: 880-7
5. O'Malley SS, Croop RS, Wroblewski JM, et al. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatry Ann 1995; 25: 681-8
6. Chick J. UK multicentre study of naltrexone as adjunctive therapy in the treatment of alcoholism: efficacy results. Proceedings X Congress World Psychiatric Association; 1996 August; Madrid: WPA, S-1112-3
7. Balldin J, Berglund M, Borg S, et al. A randomized 6 months double-blind placebo controlled study of naltrexone and coping skills educational programme. Alcohol Alcohol 1997; 32, 325
8. Acamproasate for alcohol dependence? Drugs Ther Bull 1997; 35: 70-2
9. Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1996; 15: 274-82
10. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 1997; 129: 99-111
11. Littleton J. Acamprosate in alcohol dependence: how does it work. Addiction 1995; 90: 1179-88
12. Zernig G, Fabisch H. Pharmacotherapy of alcohol dependence. Trends Pharmacol Sci 1997; 18: 229-31
13. Schuckitt MA. Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 1996; 64: 669-76
14. Wilde MI, Goa KL. Management of alcohol dependence after detoxification. The potential role of acamprosate. Dis Manag Health Outcomes 1998; 3: 35-46
15. Volpicelli JR, Volpicelli LA, O'Brien ChP. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol Alcohol 1995; 30: 789-98
16. Weinrieb RM, O'Brien ChP. Naltrexone in the treatment of alcoholism. Ann Rev Med 1997; 48: 477-87
17. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53: 217-24
18. Saitz R, O'Malley SS. Pharmacotherapies for alcohol abuse. Psychiatr Clin North Am 1997; 81: 881-907
19. Morgan M. UK Multicentre study of naltrexone as adjunctive therapy in the treatment of alcoholism: safety results. Proceedings X Congress World Psychiatric Association; 1996 August; Madrid: WPA, S-1112-4
20. Croop R. Long-term safety of naltrexone for the treatment of alcoholism. Proceedings X Congress World Psychiatric Association; 1996 August, Madrid: WPA, S-1112-5
21. King AC, Volpicelli JR, Gunduz M, et al. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 1997; 5: 906-9
22. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 1997; 54: 1130-5
23. Sandwijk JP, Cohen PDA, Musterd S. Licit and illicit drug use in Amsterdam. Report of a household survey in 1990 on the prevalence of drug use among the population of 12 years and over. Amsterdam: Inst Soc Geograf UvA, 1991
24. Freed PE, York LN. Naltrexone: a controversial therapy for alcohol dependence. J Psychosoc Nurs 1997; 35 (7): 24-8
25. Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone. Am J Psychiatry 1993; 150: 1430
26. Lerner AG, Oyffe I, Isaacs G, et al. Naltrexone treatment of hallucinogen persisting perception disorder. Am J Psychiatry 1997; 154: 437
27. Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behavior: an open-label trial. J Clin Psyshiatry 1996; 57: 233-7
28. van den Brink W. Epidemiologie en classificatie van alcoholproblemen. In: Geerlings PJ, van den Brink W, Schippers GM, editors. Behandelstrategieën bij alcoholproblemen. Houten: Bohn Stafleu Van Loghum, 1996: 1-10